title: Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual.
abstract: OBJECTIVE
  Screening logs have the potential to help oncology clinical trial programs at the site level, as well as trial leaders, address enrollment in real time. Such an approach could be especially helpful in improving representation of racial/ethnic minority and other underrepresented populations in clinical trials.
  
  
  METHODS
  The National Cancer Institute Community Cancer Centers Program (NCCCP) developed a screening log. Log data collected from March 2009 through May 2012 were analyzed for number of patients screened versus enrolled, including for demographic subgroups; screening methods; and enrollment barriers, including reasons for ineligibility and provider and patient reasons for declining to offer or participate in a trial. User feedback was obtained to better understand perceptions of log utility.
  
  
  RESULTS
  Of 4,483 patients screened, 18.4% enrolled onto NCCCP log trials. Reasons for nonenrollment were ineligibility (51.6%), patient declined (25.8%), physician declined (15.6%), urgent need for treatment (6.6%), and trial suspension (0.4%). Major reasons for patients declining were no desire to participate in trials (43.2%) and preference for standard of care (39%). Major reasons for physicians declining to offer trials were preference for standard of care (53%) and concerns about tolerability (29.3%). Enrollment rates onto log trials did not differ between white and black (P = .15) or between Hispanic and non-Hispanic patients (P = .73). Other races had lower enrollment rates than whites and blacks. Sites valued the ready access to log data on enrollment barriers, with some sites changing practices to address those barriers.
  
  
  CONCLUSIONS
  Use of screening logs to document enrollment barriers at the local level can facilitate development of strategies to enhance clinical trial accrual.
authors.affiliation: National Cancer Institute, Bethesda; SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick; The EMMES Corporation, Rockville, MD; St Joseph Hospital of Orange, Orange, CA; Billings Clinic Cancer Center, Billings, MT; Gundersen Health System, La Crosse; Waukesha Memorial Hospital (ProHealth Care), Waukesha, WI; The Cancer Program of Our Lady of the Lake and Mary Bird Perkins Cancer Center, Baton Rouge, LA; Delaware Cancer Consortium, Dover; Helen F. Graham Cancer Center, Newark, DE.
authors.forename: Diane
authors.initials: D
authors.lastname: St Germain
authors.forename: Andrea M
authors.initials: AM
authors.lastname: Denicoff
authors.forename: Eileen P
authors.initials: EP
authors.lastname: Dimond
authors.forename: Angela
authors.initials: A
authors.lastname: Carrigan
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Enos
authors.forename: Maria M
authors.initials: MM
authors.lastname: Gonzalez
authors.forename: Kathy
authors.initials: K
authors.lastname: Wilkinson
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Mathiason
authors.forename: Brenda
authors.initials: B
authors.lastname: Duggan
authors.forename: Shaun
authors.initials: S
authors.lastname: Einolf
authors.forename: Worta
authors.initials: W
authors.lastname: McCaskill-Stevens
authors.forename: Donna M
authors.initials: DM
authors.lastname: Bryant
authors.forename: Michael A
authors.initials: MA
authors.lastname: Thompson
authors.forename: Stephen S
authors.initials: SS
authors.lastname: Grubbs
authors.forename: Ronald S
authors.initials: RS
authors.lastname: Go
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D007407:Interviews as Topic; D008495:Medical Oncology; D054547:National Cancer Institute (U.S.); D018579:Patient Selection; D014481:United States